Key result
This review appraises available evidence for risk stratification in arrhythmogenic right ventricular cardiomyopathy to guide primary prevention implantable cardioverter-defibrillator therapy.
Why the study?
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy?
Does implantable cardioverter-defibrillator (ICD) therapy prevent sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy?
This review provides evidence-based guidance on risk stratification for sudden cardiac death in ARVC to inform decisions regarding primary prevention ICD therapy.
Answers are grounded in this paper and cite their sources.
Current risk stratification warrants caution for primary prevention ICD decisions in ARVC; leaves open need for validated predictors.
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) is an uncommon but increasingly recognized inherited cardiomyopathy that is associated with malignant ventricular arrhythmias and sudden cardiac death, particularly in young individuals. The implantable cardioverter-defibrillator (ICD) is widely regarded as the only treatment modality with evidence to support improved survival in patients with ARVC and secondary prevention indications. In contrast, there is no universally accepted risk stratification scheme to guide ICD therapy for primary prevention against sudden cardiac death. Potential benefits must be weighed against the considerable risks of complications and inappropriate shocks in this young patient population. This article tackles the challenges of risk stratification for sudden cardiac death in ARVC and critically appraises available evidence for various proposed risk factors. The authors' over-arching objective is to provide the clinician with evidence-based guidance to inform decisions regarding the selection of appropriate candidates with ARVC for ICD therapy.
No takes yet. Share an insight, caveat, or question.
Cadrin‐Tourigny et al. (2015) conducted a review in Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC). Implantable cardioverter-defibrillator (ICD) therapy and risk stratification was evaluated on Sudden cardiac death. This review appraises available evidence for risk stratification in arrhythmogenic right ventricular cardiomyopathy to guide primary prevention implantable cardioverter-defibrillator therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: